MemorialCare
Welcome,         Profile    Billing    Logout  
 1 Trial 
26 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tran, Thao T
NCT06228976: Mindfulness-based, Mobile Health (mHealth) Smoking Cessation Intervention in Vietnam

Recruiting
N/A
1200
RoW
Mindfulness-based, smoking cessation focused text messages., Educational messages, Control messages
Hanoi University of Public Health, Georgia State University, National Institutes of Health (NIH), Fogarty International Center of the National Institute of Health
Smoking Cessation, Mindfulness, Telemedicine, Smoking
08/24
12/24
NCT05234177: Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays

Recruiting
N/A
160
US
Observation
Tempus AI
Colorectal Cancer
02/25
02/27
Macias, Laura
ASTRIDE, NCT05468489: To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Recruiting
3
200
US
Serplulimab + chemotherapy (carboplatin-etoposide), Atezolizumab + chemotherapy (carboplatin-etoposide)
Shanghai Henlius Biotech
Extensive Stage Small Cell Lung Cancer
10/24
12/25
XPORT-EC-042, NCT05611931: Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Calendar Jul 2024 - Dec 2024: Top-line data from XPORT-EC trial in participants with TP53 wild type endometrial cancer
Recruiting
3
220
Europe, Canada, US, RoW
Selinexor, KPT-330, Matching Placebo for selinexor
Karyopharm Therapeutics Inc, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgium and Luxembourg Gynaecological Oncology Group, North Eastern German Society of Gynaecological Oncology, Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies, Spanish Research Group in Ovarian Cancer, The Central and Eastern European Gynecologic Oncology Group, Israeli Society of Gynecologic Oncology, Australia New Zealand Gynaecological Oncology Group
Endometrial Cancer
01/25
01/28
KEYNOTE B36, NCT04892472: EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer

Recruiting
2
100
US
NovoTTF-200T, Pembrolizumab (MK-3475) 200 mg
NovoCure GmbH, Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
07/24
12/26
NCT05234177: Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays

Recruiting
N/A
160
US
Observation
Tempus AI
Colorectal Cancer
02/25
02/27
Polaris, NCT06018753: Umbrella Study for Analysis of Data Related to Patients With Cancer

Recruiting
N/A
10000
US
Tempus AI
Cancer
09/28
12/28
Rao, Amol
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Canada, Japan, US, RoW
LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
11/23
05/27
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
VOICE, NCT04648020: Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer.

Terminated
2b
190
Europe, US
Clonidine HCl Mucoadhesive Buccal Tablet, Validive®, Placebo Mucoadhesive Buccal Tablet
Monopar Therapeutics
Chemoradiotherapy-Induced Severe Oral Mucositis
05/23
05/23
CA239-0010, NCT05609578: Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

Recruiting
2
90
Europe, US, RoW
Adagrasib oral dose of 400 mg twice daily tablets, Pembrolizumab, Chemotherapy: Pemetrexed, Cisplatin/Carboplatin
Mirati Therapeutics Inc.
Advanced NSCLC, Metastatic Lung Cancer
06/26
12/26
KB-0742-1001, NCT04718675: A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma

Recruiting
1/2
280
Europe, US
KB-0742
Kronos Bio
Relapsed Solid Tumors, Refractory Solid Tumors, Non-Hodgkin Lymphoma
12/25
12/25
Keynote 596, NCT02675946: CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors

Recruiting
1b
72
US, RoW
CGX1321, Pembrolizumab, Keytruda, encorafenib, Braftovi, cetuximab, Erbitux
Curegenix Inc., Merck Sharp & Dohme LLC
Solid Tumors, GI Cancer
03/23
03/23
NCT05234177: Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays

Recruiting
N/A
160
US
Observation
Tempus AI
Colorectal Cancer
02/25
02/27
NCT05236114: GEMINI-NSCLC: NSCLC Biomarker Study

Recruiting
N/A
813
US
Observation
Tempus AI, AstraZeneca
Non-Small Cell Lung Cancer
06/25
02/27
NCT04659135: ASCO Survey on COVID-19 in Oncology (ASCO) Registry

Active, not recruiting
N/A
7000
US
American Society of Clinical Oncology
Neoplasms, Coronavirus
08/24
01/25
Avadhani, Anjali
PAVO, NCT05169437: Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors

Active, not recruiting
2
22
US
Niraparib, Zejula
Tempus AI, GlaxoSmithKline
Solid Tumor, Breast Tumor, Colon Tumor, Malignant, Lung Tumor, Urologic Cancer, Pancreatic Cancer, Melanoma, Metastatic Cancer, Locally Advanced Solid Tumor, Esophageal Cancer, Endometrial Cancer, Head and Neck Cancer
06/24
01/25
NCT05236114: GEMINI-NSCLC: NSCLC Biomarker Study

Recruiting
N/A
813
US
Observation
Tempus AI, AstraZeneca
Non-Small Cell Lung Cancer
06/25
02/27
NCT06163534: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)

Recruiting
N/A
500
US
Tempus AI, AstraZeneca
Head and Neck Squamous Cell Carcinoma
03/28
03/28
NCT05257551: Tempus Sculptor Study: Small Cell Lung Cancer (SCLC) Observational Study

Recruiting
N/A
50
US
Observation
Tempus AI, AstraZeneca
Small Cell Lung Cancer
03/26
03/26
Polaris, NCT06018753: Umbrella Study for Analysis of Data Related to Patients With Cancer

Recruiting
N/A
10000
US
Tempus AI
Cancer
09/28
12/28
Collucci, Tuyet
NCT05236114: GEMINI-NSCLC: NSCLC Biomarker Study

Recruiting
N/A
813
US
Observation
Tempus AI, AstraZeneca
Non-Small Cell Lung Cancer
06/25
02/27
VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer

Recruiting
N/A
400
US
Vanquish System
Francis Medical Inc.
Prostate Cancer
04/27
04/29
Reddy, Aswanth
NCT05234177: Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays

Recruiting
N/A
160
US
Observation
Tempus AI
Colorectal Cancer
02/25
02/27
NCT05236114: GEMINI-NSCLC: NSCLC Biomarker Study

Recruiting
N/A
813
US
Observation
Tempus AI, AstraZeneca
Non-Small Cell Lung Cancer
06/25
02/27
Harris, Todd
NCT05929937: No Opioids vs. Minimal Opioids Following Inguinal Hernia Repair

Recruiting
3
904
US
Opioids, Opioid, No opioids
Clayton Petro
Postoperative Pain, Inguinal Hernia
06/27
07/27

Download Options